Mounjaro (tirzepatide) · A guide for adults in the UK
Mounjaro, explained.
The medicine and the care around it.
Understand the medicine, the assessment and the care around it. A sourced UK guide to tirzepatide for adults considering or discussing weight-management treatment.
This guide focuses on adult weight management. It does not assess your eligibility, select a dose or replace the current patient leaflet and your clinical team. Diabetes treatment has a separate care pathway. Pick My Pharmacy does not prescribe or supply medicines.
01 / The guide
What is Mounjaro, and how does tirzepatide work?
Mounjaro is a brand of tirzepatide. It acts on GIP and GLP-1 receptors, which are involved in appetite and blood-glucose regulation. It is supplied only on prescription.
For weight management, the medicine is used with a reduced-calorie diet and increased physical activity. It is also used in a separate type 2 diabetes pathway. This page focuses on adult weight management; do not use it to change diabetes care.
An informed discussion should cover why a medicine is being considered, what benefit is realistic for you and what care will accompany it. The ability to purchase a private consultation does not establish that the treatment is appropriate.
02 / The guide
Who is Mounjaro licensed for in weight management?
The UK weight-management indication is for adults with an initial BMI of at least 30 kg/m², or at least 27 but below 30 with a weight-related health problem, alongside diet and activity support.
These licence criteria describe an authorised use. A prescriber must still assess your medical history, medicines, potential risks and circumstances. They are not an instruction to prescribe, a self-assessment result or a guarantee that a private provider will accept you.
NHS access involves additional recommendations and funding arrangements. Ask the clinician to explain which framework applies to your appointment. If you have a BMI result from an online calculator, take it as a starting point for discussion rather than approval for treatment.
Swipe or scroll sideways to compare all columns
| Framework | What it tells you | What it does not tell you |
|---|---|---|
| Product licence | The authorised uses and product information. | Whether it is suitable for a particular person. |
| NICE recommendation | When a treatment is recommended for the NHS. | That every local service can immediately offer an appointment. |
| Clinical assessment and local access | Whether the care is appropriate and available through that route. | That a private prescription creates an entitlement to NHS continuation. |
Guidance: Eli Lilly via emc: Mounjaro product information · NICE TA1026: tirzepatide for overweight and obesity
03 / The guide
Can I get Mounjaro on the NHS?
NHS use for weight management is subject to clinical criteria and service arrangements. In England, access through primary care is phased; NICE eligibility alone does not guarantee immediate supply.
NICE TA1026 recommends tirzepatide for adults with an initial BMI of at least 35 kg/m² and at least one weight-related comorbidity, alongside diet and activity support. Lower BMI thresholds, usually reduced by 2.5 kg/m², apply to the ethnic backgrounds specified in the guidance. Ask the clinician how that applies to you.
As checked on 7 September 2026, NHS England’s patient information describes possible primary-care access at BMI 35 or above, adjusted for ethnicity, with four qualifying conditions. These are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Specialist services and the phased commissioning rules need to be considered separately.
Check the current pathway with your GP practice or integrated care board. England’s rollout is not a UK-wide rule: Scotland, Wales and Northern Ireland have separate health-service arrangements. Diabetes prescribing also follows a separate assessment. A privately started course should not be assumed to transfer automatically to NHS funding.
Read NHS England’s current weight-management injection guidance
Guidance: NICE TA1026: tirzepatide for overweight and obesity · NHS England: current weight-management injection access · NHS England: interim commissioning guidance, April 2026
04 / The guide
What should the assessment cover before starting?
Expect a clinical review of your health history, medicines and relevant measurements, plus a discussion of alternatives, adverse effects and follow-up. Completing a questionnaire does not guarantee treatment.
Tell the prescriber about all medicines and supplements, including any previous weight-management products. Discuss pregnancy plans, eating-related concerns, previous adverse effects and upcoming procedures. Ask which information must be checked with your usual healthcare team.
For online weight-management prescribing, GPhC guidance requires independent verification of weight, height and/or BMI. The provider should explain how it verifies the information and what happens if an in-person assessment is needed. A phone call alone is not an appropriate way to verify these measurements.
Ask for a plan that explains who is prescribing, which pharmacy would dispense, who handles results and how to contact a clinician between routine reviews. The answers should be available before you commit to an ongoing service.
Guidance: GPhC: safeguards for distance pharmacy services · MHRA: GLP-1 medicines — what you need to know
05 / The guide
What side effects and warning signs should I know about?
Digestive adverse effects can occur, including nausea, vomiting and diarrhoea. Some symptoms need prompt clinical attention. Read the complete current leaflet and the advice from your prescriber.
Vomiting or diarrhoea can lead to dehydration. Ask your clinical team what to do if you cannot keep fluids down or feel unwell. A review is particularly important if symptoms affect your ability to eat, drink or manage other medicines. Do not assume that a severe symptom is an expected part of treatment.
MHRA strengthened pancreatitis warnings for GLP-1 and dual GIP/GLP-1 medicines in January 2026. Severe, persistent abdominal pain, particularly if it spreads to the back, may be a warning sign and needs urgent medical attention.
The risks and monitoring needs differ with your other conditions and medicines. Low blood glucose is a concern when tirzepatide is used with certain diabetes medicines, including insulin or a sulphonylurea. Your diabetes team should explain the checks and actions relevant to you.
- Seek urgent medical help for severe abdominal pain that does not settle, especially with pain spreading to your back.
- Call 999 for severe breathing difficulty, swelling of the mouth or throat, or collapse that may indicate a serious allergic reaction.
- Contact the clinical team promptly for persistent vomiting, inability to keep fluids down or other concerning symptoms. This is not a complete list of adverse effects.
Guidance: MHRA: strengthened pancreatitis warnings, January 2026 · MHRA: GLP-1 medicines — what you need to know · Eli Lilly via emc: current Mounjaro KwikPen patient leaflet
06 / The guide
What should I ask about contraception, pregnancy and other medicines?
Tirzepatide should not be used during pregnancy. Discuss pregnancy plans and contraception before starting, and tell the clinician about other medicines and any planned anaesthetic or procedure.
MHRA advises people taking an oral contraceptive to use a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Ask a pharmacist or clinician to explain how this applies to your contraception and what to do if vomiting or diarrhoea also affects it.
Ask your prescriber how far in advance treatment needs to stop before a planned pregnancy; do not improvise a stopping or restarting plan. If you think you may be pregnant, contact a healthcare professional promptly.
For breastfeeding, get medicine-specific advice before starting or continuing. The current Mounjaro patient leaflet directs people who are breastfeeding to discuss this with their doctor. General older GLP-1 advice and individual product information may differ, so use the current leaflet with your clinical team.
Tell an anaesthesia team that you use tirzepatide before surgery or deep sedation. The team should advise on your individual plan; do not change treatment solely because of a general online instruction.
Guidance: MHRA: contraception advice for tirzepatide · Eli Lilly via emc: current Mounjaro KwikPen patient leaflet · MHRA: GLP-1 medicines — what you need to know
07 / The guide
Where should I find instructions about doses, missed doses and storage?
Use the current patient leaflet, pen instructions and the plan from your prescriber. Tirzepatide is given as a weekly injection; changes in dose require clinical guidance.
Ask the pharmacy to show you how to use the exact pen supplied and how to handle needles and sharps disposal. Check the label matches your prescription. If an instruction is unclear, resolve it with the pharmacy before using the pen.
For a missed dose, use the medicine-specific leaflet or ask your pharmacist; do not double a dose to catch up. If you have stopped for a period, contact the prescriber before restarting. Do not try to extract leftover liquid as an extra dose or calculate doses by counting pen clicks.
Ask about storage before and after first use, travel and what to do if a delivery arrives warm or damaged. The pharmacy can assess the specific situation against the product instructions. Keep the packaging and do not guess whether a temperature excursion is acceptable.
Read the current Mounjaro KwikPen patient leaflet
Guidance: Eli Lilly via emc: current Mounjaro KwikPen patient leaflet
08 / The guide
How should I interpret Mounjaro weight-loss results?
Research describes average outcomes in defined groups. It cannot predict your personal response, and results need to be read with the study population, duration, adverse effects and support provided.
The SURMOUNT-1 randomised trial studied 2,539 adults with obesity, or overweight with a related complication, who did not have diabetes. At 72 weeks, average weight reductions were 15.0%, 19.5% and 20.9% in the three tirzepatide groups, compared with 3.1% with placebo. Treatment included lifestyle support; gastrointestinal adverse effects were common and some participants stopped treatment because of adverse events. The trial was funded by Eli Lilly.
These are group averages from a particular trial, not a promise or a target for every person. Results from other populations or different study designs should not be combined into a simple “best medicine” ranking. A clinician needs to weigh potential benefit against suitability, tolerability and your priorities.
Ask what a meaningful result would look like for your health, how it will be reviewed and what the plan is if treatment does not help enough. A larger dose or an impressive advert is not a reason to change your prescription yourself.
Guidance: SURMOUNT-1: randomised trial in adults without diabetes
09 / The guide
What should ongoing care include?
Agree regular reviews of benefit, adverse effects, nutrition, activity and any relevant medical monitoring. Access to repeat supplies is only one part of a care plan.
NHS England describes wraparound care for primary-care tirzepatide prescribing as both clinical review and behavioural support. Ask a private service to explain its own arrangements just as clearly: what contact is included, which professional provides it and how concerns are escalated.
NICE considers whether to continue treatment if less than 5% of initial weight has been lost after six months on the highest tolerated dose, taking account of individual benefits and risks. This is a clinician’s review decision, not an instruction to stop on your own.
Discuss stopping, weight maintenance and any need to transfer care before circumstances force a quick decision. In the SURMOUNT-4 withdrawal trial, participants switched to placebo after an initial tirzepatide period regained weight on average, while those continuing treatment maintained and extended weight reduction. The study does not determine the right duration for every person.
Guidance: NHS England: clinical and behavioural support with tirzepatide · NICE TA1026: tirzepatide for overweight and obesity · SURMOUNT-4: continued treatment and withdrawal trial
10 / The guide
How much does Mounjaro treatment cost privately?
There is no single live price that applies to every service, strength and care plan. Ask for a dated, written quote covering the assessment, any prescribed supply, follow-up and delivery.
The lowest advertised starting price is not a reliable estimate of a full year of care. Your prescribed plan may change, fees may change and different providers include different support. This page does not display a price range without current, comparable provider evidence.
Ask how fees work if treatment is unsuitable, you need a review before further supply or your plan changes. A prescription does not remove the need to understand renewal and cancellation terms. Budget for the complete service rather than assuming each future month will cost the same.
| Part of the service | What to establish |
|---|---|
| Assessment | Initial fee, any separate clinical appointment and terms if treatment is declined. |
| Prescribed supply | The exact strength, quantity and period covered by the quote. |
| Equipment and delivery | Needles, sharps disposal, delivery charges and temperature-handling arrangements. |
| Clinical and behavioural support | Who provides reviews, how often they happen and how questions are handled between them. |
| Renewal and stopping | Automatic payments, cancellation terms and how fees change with the care plan. |
Compare the questions to ask about UK weight-management services
11 / The guide
How do I check the pharmacy and avoid unsafe supply?
Check the dispensing pharmacy on the appropriate live register and identify the prescriber. Mounjaro is prescription-only; a social-media offer is not evidence of legitimate supply.
Use the GPhC register for a pharmacy in Great Britain and the PSNI register for Northern Ireland. Match the premises details and confirm the website belongs to that business. A clinic and the pharmacy it uses may be separate organisations.
Ask how to report a damaged or questionable product and how to obtain urgent clinical advice. Do not buy powders for self-mixing, share a prescription pen or rely on a seller’s claim that no assessment is needed. If you suspect a medicine is counterfeit, contact the pharmacy or MHRA for advice.
How to choose a safe online pharmacy
Guidance: GPhC: pharmacy register · PSNI: Northern Ireland pharmacy register · MHRA: GLP-1 medicines — what you need to know
12 / The guide
What should I ask before agreeing to a treatment plan?
Use this checklist to prepare for a clinical conversation. It does not calculate eligibility or recommend a medicine.
Choose the questions that matter to you and print the guide if useful. No weight, medicine history or health details are collected here, and your selections are not submitted or saved by this page.
0 of 8 questions selected
Prepare questions for your GP on our sister website HealthAnswers
A few more answers
Common mounjaro (tirzepatide) questions
Is Mounjaro the same as tirzepatide?
Mounjaro is a brand name; tirzepatide is its active ingredient. The exact formulation and instructions should match the product prescribed and supplied.
Can I obtain Mounjaro without a prescription?
No. It is a prescription-only medicine. A qualified prescriber must assess suitability, and a pharmacy must have a lawful basis to supply it.
Does meeting the BMI threshold guarantee treatment?
No. Licence criteria, NICE recommendations, NHS access arrangements and an individual clinical decision are separate. The prescriber can decide the medicine is unsuitable.
Is the England NHS rollout the same across the UK?
No. NHS England’s phased approach applies to England. Ask the relevant local NHS service in Scotland, Wales or Northern Ireland about its pathway.
Can Mounjaro affect the contraceptive pill?
Yes. MHRA advises a non-oral method or an additional barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. Discuss the plan with a pharmacist or clinician.
What should I do if I miss a dose or want to restart?
Use the current patient leaflet and contact your pharmacist or prescriber if unsure. Do not double up or restart a previous dose after a gap without appropriate advice.
Can I use liquid left in a KwikPen as an extra dose?
No. Do not extract leftover liquid or improvise a dose. Follow the manufacturer’s instructions for the pen and safe disposal.
Will everyone achieve the weight loss reported in trials?
No. A trial average is not an individual prediction. Population, duration, support and tolerability all affect interpretation; agree meaningful goals with your clinician.
Can I switch between Mounjaro and another weight-management medicine myself?
No. A switch needs a clinical review and a specific plan. Do not combine medicines or use a comparison page as dosing instructions.
Does this page sell treatment or recommend a provider?
No. It provides general educational information and links to source guidance. Pick My Pharmacy does not prescribe or supply medicines.
Where this information comes from
Sources & editorial notes
This guide draws on the public health and regulator guidance listed below. Sources were checked on 7 September 2026. It is educational information from Pick My Pharmacy; it has not been independently clinically reviewed.
Service availability, eligibility and individual care decisions can change. Use the original guidance and your healthcare professional for decisions about your care. Commercial relationships do not determine the clinical guidance above.
- Eli Lilly via emc: Mounjaro product informationChecked
- Eli Lilly via emc: current Mounjaro KwikPen patient leafletChecked
- NICE TA1026: tirzepatide for overweight and obesityChecked
- NHS England: current weight-management injection accessChecked
- NHS England: interim commissioning guidance, April 2026Checked
- NHS England: clinical and behavioural support with tirzepatideChecked
- MHRA: GLP-1 medicines — what you need to knowChecked
- MHRA: contraception advice for tirzepatideChecked
- MHRA: strengthened pancreatitis warnings, January 2026Checked
- GPhC: safeguards for distance pharmacy servicesChecked
- GPhC: pharmacy registerChecked
- PSNI: Northern Ireland pharmacy registerChecked
- SURMOUNT-1: randomised trial in adults without diabetesChecked
- SURMOUNT-4: continued treatment and withdrawal trialChecked